BridgeBio Oncology Therapeutics Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BBOT research report →
Range $15 – $22
Price Chart
About the company
BridgeBio Oncology Therapeutics, Inc. , a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models.
- CEO
- Pedro J. Beltran
- IPO
- 2025
- Employees
- 88
- HQ
- South San Francisco, CA, US
Get TickerSpark's AI analysis on BBOT
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $284.38M
- P/E
- -0.00
- PEG
- 0.00
- P/S
- 0.00
- P/B
- 0.00
- EV/EBITDA
- -1.20
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -46.90%
- ROIC
- -61.10%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-145,819,000
- Net Income
- $-134,044,000-80.5%
- EPS
- $-4.30+99.9%
- OCF Growth
- -14811.1%
- FCF Growth
- -14890.4%
- 52W High
- $14.87
- 52W Low
- $3.54
- 50D MA
- $7.27
- 200D MA
- $9.02
- Beta
- 0.39
- RSI (14)
- 18
- Avg Volume
- 470.58K
No earnings-call transcripts are available for BBOT yet.
- Free Float
- 0.6%
- Shares Outstanding
- 80.11M
- Float Shares
- 452.99K
of shares held by institutions
67 13F filers
Buy/sell ratio 3.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Cormorant Asset Management, LP | 17.88M | 0 |
| Deerfield Management Company, L.P. (Series C) | 4.89M | 0 |
| Omega Fund Management, LLC | 3.29M | 0 |
| Alphabet Inc. | 2.82M | 0 |
| Ecor1 Capital, LLC | 2.82M | 0 |
| Wellington Management Group Llp | 2.79M | ▼ 29.05K |
| Enavate Sciences Gp, LLC | 2.63M | 0 |
| Citadel Advisors LLC | 2.62M | ▲ 89.06K |
| Novo Holdings A/S | 2.25M | ▲ 64.08K |
| Blackrock, Inc. | 2.15M | ▲ 65.74K |
| Vanguard Capital Management LLC | 2.01M | ▲ 1.47M |
| Laurion Capital Management LP | 2.00M | ▲ 80.05K |
Held by 52 ETFs
Biggest fund positions in BBOT by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 1, 26 | Cobo Marc | other | 126 |
| Oct 1, 26 | Elmelech Idan | other | 343 |
| Oct 1, 26 | Beltran Pedro | other | 1,047 |
| Oct 1, 26 | Ben Yong | other | 1,047 |
| Sep 10, 26 | Cobo Marc | other | 43,700 |
| Sep 10, 26 | Cobo Marc | other | 9,038 |
| Sep 10, 26 | Cobo Marc | other | 203 |
| Jul 1, 26 | Cobo Marc | other | 125 |
| Jul 1, 26 | Elmelech Idan | other | 343 |
| Jul 1, 26 | Ben Yong | other | 1,047 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our BBOT coverage
Recent articles, reports, and earnings notes.
No research on BBOT yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BBOT report →Brokerages Set BridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT) Price Target at $22.88
defenseworld.net · Sep 16
BBOT Announces New BBO-8520 Data; Highlights Strategic Focus on 2L+ NSCLC BBO-8520 Combination as Well as BBO-11818 and BBO-10203 Combinations in KRAS-Mutant Cancers
globenewswire.com · Sep 8
BBOT to Participate in Upcoming Investor Healthcare Conferences
globenewswire.com · Sep 1
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com · Aug 11
BBOT Reports Second Quarter 2026 Financial Results and Update on Corporate Progress
globenewswire.com · Aug 11
BridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT) Receives $24.80 Average PT from Brokerages
defenseworld.net · Jul 28
BridgeBio Oncology Therapeutics: KRAS Program Data Due 2H26 May Reignite Bullish Sentiment
seekingalpha.com · Jul 13
BBOT Reports First Quarter 2026 Financial Results and Update on Corporate Progress
globenewswire.com · May 12
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.